EDMONTON, May 10 /CNW/ - BioMS Medical Corp (TSX: MS - News), a leading developer in the treatment of multiple sclerosis (MS), today announced it has received approval from the Danish Medicines Agency to start patient enrolment in Denmark for its pivotal phase II/III clinical trial of MBP8298, a proprietary synthetic peptide for the treatment of secondary progressive multiple sclerosis (SPMS).
